2,274
Participants
Start Date
July 2, 2018
Primary Completion Date
June 30, 2022
Study Completion Date
June 30, 2022
Infliximab
Administered as specified in the treatment arm.
Adalimumab
Administered as specified in the treatment arm.
Research Site, Caluire-et-Cuire
Research Site 1, Clermont-Ferrand
Research Site, Clermont-Ferrand
Research Site, Lyon
Research Site 1, Pierre-Bénite
Research Site, Pierre-Bénite
Research Site, Saint-Etienne
Research Site, Dijon
Research Site 1, Brest
Research Site, Brest
Research Site, Rennes
Research Site, Chambray-lès-Tours
Research Site, Orléans
Research Site, Reims
Research Site, Strasbourg
Research Site 1, Vandœuvre-lès-Nancy
Research Site, Vandœuvre-lès-Nancy
Research Site, Amiens
Research Site 1, Lille
Research Site, Lille
Research Site, Caen
Research Site, Rouen
Research Site, Bayonne
Research Site, Bordeaux
Research Site 1, La Rochelle
Research Site 2, La Rochelle
Research Site, La Rochelle
Research Site, Limoges
Research Site 1, Montpellier
Research Site, Montpellier
Research Site 1, Nîmes
Research Site, Nîmes
Research Site 1, Toulouse
Research Site, Toulouse
Research Site, Angers
Research Site 1, Nantes
Research Site, Nantes
Research Site, Cannes
Research Site, La Crau
Research Site 1, Marseille
Research Site, Marseille
Research Site, Nice
Research Site, Toulon
Research Site 1, Bobigny
Research Site, Bobigny
Research Site, Clichy
Research Site, Colombes
Research Site, Créteil
Research Site, Le Kremlin-Bicêtre
Research Site 10, Paris
Research Site 1, Paris
Research Site 2, Paris
Research Site 3, Paris
Research Site 4, Paris
Research Site 5, Paris
Research Site 6, Paris
Research Site 7, Paris
Research Site 8, Paris
Research Site 9, Paris
Research Site, Paris
Lead Sponsor
Biogen
INDUSTRY